Gastroenteritis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 58 pages | ID: G361927277AFEN
VPAResearch

Abstracts

2020 Gastroenteritis PIPELINE HIGHLIGHTS
Gastroenteritis is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline’s potential. Development of Gastroenteritis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Gastroenteritis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Gastroenteritis.

Good progress is anticipated during 2020 and 2021 with Gastroenteritis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Gastroenteritis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Gastroenteritis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Gastroenteritis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Gastroenteritis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Gastroenteritis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Gastroenteritis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Gastroenteritis DRUG PROFILES
Gastroenteritis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Gastroenteritis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Gastroenteritis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Gastroenteritis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 8 Gastroenteritis companies including company overview, key snapshot, contact information, and their strategies on accelerating Gastroenteritis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Allakos Inc, Kyowa Kirin Co Ltd, Medicago Inc, Novo Medi Sciences Pvt Ltd, RedHill Biopharma Ltd, Regeneron Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, UMN Pharma Inc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Gastroenteritis
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO GASTROENTERITIS

1.1 Gastroenteritis- Disease overview
1.2 Gastroenteritis- Market Size
1.3 Gastroenteritis- Companies Involved

2. GASTROENTERITIS PIPELINE SNAPSHOT- 2020

2.1 Gastroenteritis Pipeline by Phase
2.2 Gastroenteritis Pipeline by Mechanism of Action
2.3 Gastroenteritis Pipeline by Route of Administration
2.4 Gastroenteritis Pipeline- New Molecular Entities
2.5 Gastroenteritis Pipeline- Orphan Drug Designation/ Special Designation

3. GASTROENTERITIS DRUG PROFILES

3.1 Current Status
3.2 Gastroenteritis Drug Snapshot
3.3 Gastroenteritis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Allakos Inc Gastroenteritis Pipeline Insights and Clinical Trials
4.2 Kyowa Kirin Co Ltd Gastroenteritis Pipeline Insights and Clinical Trials
4.3 Medicago Inc Gastroenteritis Pipeline Insights and Clinical Trials
4.4 Novo Medi Sciences Pvt Ltd Gastroenteritis Pipeline Insights and Clinical Trials
4.5 RedHill Biopharma Ltd Gastroenteritis Pipeline Insights and Clinical Trials
4.6 Regeneron Pharmaceuticals Inc Gastroenteritis Pipeline Insights and Clinical Trials
4.7 Takeda Pharmaceutical Co Ltd Gastroenteritis Pipeline Insights and Clinical Trials
4.8 UMN Pharma Inc Gastroenteritis Pipeline Insights and Clinical Trials

5. GASTROENTERITIS MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information